About-cancer/treatment/drugs/caplacizumab-yhdp

From loveco.care
Revision as of 21:18, 29 October 2019 by Dengjun (talk | contribs) (Marked this version for translation)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Other languages:
English • ‎中文

Caplacizumab-yhdp

This page contains brief information about caplacizumab-yhdp and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Cablivi

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Caplacizumab-yhdp is approved to treat:

  • Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.

More About Caplacizumab-yhdp

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.

Retrieved from "http://www.loveco.care/index.php?title=About-cancer/treatment/drugs/caplacizumab-yhdp&oldid=2966"